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Abstract
The importance of studying the human papillomavirus (HPV) is because it is a 
disease that relies on 14 HPV types classified as carcinogenic high risk and that con-
tributes to cervical cancers affecting approximately 527,600 women yearly and caus-
ing 265,387 deaths yearly, being the second mortality cause for women globally. In 
Mexico, 13.9% of demises are due to cervical uterine cancer (CUCA). The challenges 
for a vaccine that may prevent HPV occurrence are an active field for scientists with 
significant advances but still undergoing for a full cure to this disease. In this work, 
latest research trends to treat HPV are analyzed, and by means of molecular cou-
pling analysis, a modeling and simulation process to predict interactions of leader 
molecules with the target for synthetic elaboration of a possible therapeutic treat-
ment is developed. One of the main topics discussed in this chapter relates to new 
drug design for HPV treatment, which is related to the inhibitors of protein-protein 
interactions and in the protein drugs. Regarding HPV therapy development, a group 
of small molecules has been identified using high-performance sieving capable of 
interrupting HPV16 E1-E2 interaction, which helps avoid viral replication. Some of 
these compounds displayed nanomolar affinities and high specificity.
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1. Introduction
Human papillomavirus (HPV) belongs to the Papillomaviridae family, according 
to the eighth report developed by the International Committee for Viral Taxonomy. 
To date, over 100 different HPV types have been cataloged and around 30 infected 
anogenital mucosae. HPV types are classified as virus from low to high risk accord-
ing to their capability to cause benign or carcinogenic injuries, respectively [1].
Infection provoked by HPV is one of the more common causes among sexually 
transmitted diseases with prevalence levels varying between the population and 
geographic location.
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At least 14 types of them are classified as carcinogenic high risk (hr-HPV); 
among them HPV16 and HPV18 are responsible for around 70% of all cervical 
cancers affecting approximately 527,600 women yearly and causing 265,387 deaths 
yearly, being the second mortality cause for women globally [2]. Over 85% of new 
cases and deaths referred occur in developing countries [3] such as Mexico, where 
13.9% of demises are due to cervical uterine cancer (CUCA) [4].
The challenges for a vaccine that may prevent HPV occurrence is an active field 
for scientists with significant advances but still undergoing for a full solution that 
can eliminate this disease.
In this work latest research trends to treat HPV are analyzed, and by means of 
molecular coupling analysis, a modeling and simulation process to predict interac-
tions of leader molecules with the target for synthetic elaboration of a possible 
therapeutic treatment is developed.
This chapter is a review of the latest advances on new drug design for HPV 
treatment which are related to the inhibitors of protein-protein interactions and in 
the protein drugs. Regarding HPV therapy development, a group of small molecules 
has been identified using high -performance sieving capable of interrupting HPV16 
E1-E2 interaction which helps avoid viral replication. Some of these compounds 
displayed nanomolar affinities and high specificity.
2. HPV genome, treatment, and prevention
2.1 HPV infection, treatment, and prevention
Currently, an antiviral treatment is unavailable that can help eliminate the infec-
tion or avoid progression of injuries caused by CUCA. Current therapies for cervical 
dysplasia and cancer implicate destruction or elimination of infected tissue by cyto-
toxic agents or surgery [5]. On the other hand, FDA has approved three vaccines 
for HPV infection prevention: Gardasil, Gardasil 9, and Cervarix. All three prevent 
HPV infection types 16 and 18 [6, 7]. Gardasil also protects HPV infection types 6 
and 11, which cause 90% of genital warts [8]. Gardasil 9 protects from infection 
of the same four HPV types and other five HPV types (31/33/45/52/58) that cause 
cancer [9]. These vaccines are based in empty particles similar to the “ghost” virus, 
formed by L1 protein capsid from each viral type [8, 10]. It has been demonstrated 
that these vaccines are highly protective against the lesions of transformed cells at 
an early stage that represent cervical cancer precursors. Since HPV 16 and HPV 18 
currently represent the two HR-HPV more common in most geographical locations, 
universal adoption of the vaccines may protect more than two-thirds of HPV-
induced cancers [10].
However, vaccination programs are not implemented worldwide, and coverage is 
still very low especially in low-income countries [10, 11].
It has been estimated that the addition of HPV 31/33/45/52/58 to the nine-valent vac-
cine could prevent almost 90% of cases of invasive cervical cancer worldwide [12, 13].
HPV vaccines currently available are useful tools in the fight against HPV 
infections and cancers but provide an incomplete answer for long-term HPV 
disease eradication. By their very nature of being capable of inducing a strong and 
protective humural—but no cellular—host immune response, they are also of little 
therapeutic value to already infected patients [10].
Scientists are working in new HPV therapeutic vaccines which may help avoid 
cancer formation in women previously infected with HPV [14]. These vaccines 
work by stimulating the immune system to attack and destroy infected cells. 
Clinical studies under development are evaluating safety and efficiency of a DNA 
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therapeutic vaccine to treat injuries by HPV in the cervix and vulva. An ideal 
strategy would be to combine a preventive and a therapeutic vaccine. Another 
prevention strategy under testing is using external microbicidal. It has been found 
that carrageenan, a compound that can be extracted from seaweeds and extensively 
used in foods and other products, inhibits HPV infection in laboratory studies. A 
clinical study is under development to demonstrate if a gel containing carrageenan 
is capable to prevent genital infection by HPV in healthy individuals [15–17].
2.2 HPV genome
HPV genome (Figure 1) consists of a circular double-chain DNA molecule of 
approximately 8 Kb in size. The genome is organized in three regions. The region 
early contains the genes E1–E8 that code predominately for regulatory proteins 
essential for viral transcription and replication, as well as cell cycle control; the late 
region encodes for the two viral structural proteins, L1 and L2, needed for capsid 
formation and the noncoding region also known are long control region (LCR) or 
upstream regulatory region (URR). The LCR region varies in size between 800 and 
1000 pb for the different HPV types, does no encodes any protein but, contains Cis-
elements required for regulation of genes expression and genome replication [18].
2.3 HPV life cycle
HPV life cycle is coupled to the differentiation cell program experienced by epi-
thelium keratinocytes. PVs are highly specific from the species they infect and present 
a tropism defined by epithelial scaly cells infecting undifferentiated basal cells.
Figure 1. 
Representation of HPV genome organization in a circular chain displaying the DNA molecule. LCR is the 
region noncoding the open reading frames (ORFs) encode the early (E) and late (L) viral proteins [18].
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During epithelium mucosa infection, firs of all, virions need to reach the undif-
ferentiated basal cells. Once in contact with blank cells, virion is associated with 
putative receptors such as alpha integrins, heparins, and laminins probably through 
wounds or microabrasions that give access to basal zones at the epithelium [19].
Heparin sulfate proteoglycans (HSPGs) from the cellular surface seem to be the 
primary receptor for initial binding [20]. The joint together is mediated by the last 
15 amino acids from the extreme carboxyl-terminal of L1 protein [21]. Virions enter 
the cell by endocytosis by using the clathrin-dependent route. Decapsidation of the 
particle occurs at the endosome, releasing the capsid genome and proteins in the 
endocytic vesicles [22].
After HPV infects basal cells, viral genome is established as a multiple copies 
episome at the cells’ nuclei through several viral DNA replication cycles.
Conservation of the viral episome at 50–100 copies at these undifferentiated 
cells is obtained then through low DNA replication levels, and it is essential for 
the infection persistence; by itself it is a risk factor for carcinogenesis induced by 
the virus; the first proteins to express themselves are the viral replication proteins 
E1 and E2. E2 protein presents a characteristic regulating function affecting the 
transcription, the replication, and the episome conservation [20, 23].
During the productive infection, viral protein detection at the basal layers 
barely exists, even though E7 protein may be detected by cervical neoplasia, where 
the expression levels cannot be controlled properly [23]. Proliferative basal cells 
would migrate to parabasal and intermediate layers, starting the differentiation 
program and with it the transcription of the different early viral genes, regulated 
through the LCR region. During this period DNA will replicate hundreds of copies 
by cell, thanks to E6 and E7 proteins which will block the exit of cells from the 
cellular cycle [24].
During productive infection, HPV proteins cannot easily be detected in the basal 
cell layer, although the E7 protein can be seen in cervical neoplasia where expression 
levels are not properly controlled.
As HPV-infected cells divide and differentiate, the late HPV promoter is acti-
vated mediated by transcription factors dependent on the differentiation, this has 
as consequence the amplification of the viral DNA, and an increase in the levels of 
viral proteins needed for replication, including E1, E4 and E5, being E4 the more 
abundant.
It has been suggested that E7 continuous expression in a cell containing abun-
dant E4 which favors the conservation of the cell in phase S, this allows the viral 
genome accumulation.
When basal cells enter the differentiation process that will convert them into 
keratinocytes, at the same time they migrate to superior layers in the epithelium 
that will cause an explosion in the viral DNA replication, known as vegetative 
replication.
Finally, both proteins and the capsid (L1 and L2) are expressed only in cells that 
have passed through the vegetative viral amplification. At the end of the productive 
cycle, genomes will encapsidate, generating virions that will be let out with release 
of superior layer cells from the mucous epithelium [23].
HPV DNA replication initiates with the cooperative join of E1 and E2 with 
specific DNA sequences inside the viral origin [15–17]. Formation of this ternary 
compound E1-E2-ori depends on the interaction between both proteins with DNA, 
but also there is a critical interaction between the E2 transactivation domain of 
N-terminal (TAD) and the E1 enzymatic domain of E1 C-terminal [25]. Assembly 
of this initial complex E1-E2-ori is the starting point for additional E1 molecule 
recruitment [26, 27] and its assembly in hexamers and double hexamers that 
display activity in ATPase and helicase [28, 29]. Any of the protein–protein and 
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protein-DNA interactions produced in the origin could be directed toward the 
development of small antiviral molecules to treat infections by HPV.
It has been demonstrated clearly that expression E1 and E2 proteins from dif-
ferent HPV genomes can induce replication of the genomic integrated HPV origin 
[30], and this is a particular danger in the presence of DNA damage [31]. Then, 
anti-HPV agents unblocking viral DNA synthesis could, in time, benefit cancer 
development increasing HPV genome integration. Due to E1 and E2 capability to 
induce HPV DNA integration, HPV DNA replication through E1 interactions with 
cellular replication proteins probably may represent one of the best approaches 
to develop an HPV antiviral that also prevents HPV integration at the host cell 
chromosomes.
2.4 E1 and E2 proteins as therapeutic targets
E1 is the most conserved protein among the papillomavirus and the only with 
enzymatic activity [32, 33]. This situation adds up to the fact that viral DNA replica-
tion is absolutely dependent on E1, and it has contributed to do an attractive target 
out of this protein so antiviral agents may be developed.
E1 gene is the bigger and one of the more conserved PVs with approximately 2 
Kb, and it codifies E1 multimeric protein [28].
E1 protein has three functional domains. C-terminal domain has helicase/
ATPase, and it participates in viral DNA replication and includes sequences 
involved in the protein oligomerization [34, 35].
Variable length central region contains the DNA-binding domain (DBD), which 
recognizes specific sites at the ori but with low affinity [36–38], and an N-terminal 
regulator region which is essential for live optimal replication [39, 40].
The last one codifies several functional elements, such as a nuclear localiza-
tion sequence (NLS), a nuclear export sequence (NES), a joint cyclin motif, and 
Cdk2 phosphorylation sites. E1 N-terminal regulator region for HPV anogenital 
type also interact with cellular p80 protein known alternatively as UAF1 or 
WDR48 [41].
Terminal carboxyl domain and spacer region have been widely studied. 
However, N-terminal domain functions have not been well defined other than those 
related to the nuclear location [35].
DBD of E1 protein consists in a sequence of 60 pb approximately. This sequence 
contains three elements, a sequence rich in A and T, a palindrome sequence found at 
LCR, forming hexamers and double hexamer, and a 12 pb sequence that constitutes 
a joining site for E2 protein [42, 43].
DBD has been widely characterized in vitro and it was the first E1 domain to be 
crystallized [43–45]. And this reveals an unusual joint mode to DNA by an extended 
bond and an α helix forming a continuous surface as DNA join.
Even though DBD more important function is to recognize and mark the ori, 
it has other functions as well. DBD performs an important role in the fusion of 
bicatenary DNA and the formation of hexameric replicative helicase [43].
The E1 N-terminal region is formed by 200 amino acids approximately; it is the 
less preserved segment of this protein. This region contains a number of motifs 
from short sequence amino acids preserved as variable among different PVs, includ-
ing a nuclear localization signal (NLS), a nuclear export signal of dependent-Crm1 
(NES), and a joining motif to the cyclin (CBM) that interacts with cyclin A/E in 
complex with kinase dependent of cyclin 2 (Cdk2) and Cdk2 phosphorylation sites 
and other kinases [40, 46, 47].
The E2 gene has approximately 1100 bp codifies a nuclear protein of 45 kDa 
[18, 48], E2 protein is composed of three functional domains. The first, at 
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the extreme amino terminal, is the activation domain (E2TAD), responsible 
of regulating the transcription and replication of the viral genome [18, 48]. 
The second domain is a hinge or central domain, with more variable length 
and sequence among the HPVs. The third domain at the carboxyl-terminal is 
for dimerization and binding with the DNA, and it is formed by 100 amino 
acids approximately [18, 48, 49] . Crystal structure E2 protein from all viral 
strains have in common the fact of joining a palindromic DNA sequence 
(ACCgNNNNcGGT, lower case letters indicate preferred nucleotides; NNNN 
region is called spacing region), referred as the E2 union site. Nevertheless, 
there are specific differences in viral strains in regard to E2 protein ability to 
discriminate union sites [48] (Figure 2).
HPV protein E2 displays independent complex functions regarding the tran-
scription and may be able to modulate host cells with respect to the viral replication 
cycle [48–50].
3. Computational modeling of E1 and E2 inhibitors
Several pharmaceutical companies have invested resources in the identification 
of E1 ATPase/helicase inhibitors. Even though small molecules have been identified 
as capable to inhibit this enzyme activity, unfortunately, none of these projects 
has resulted in a viable therapy. In late years, antiviral research has begun to deal 
with the vital interactions modulation between proteins and proteins as a feasible 
therapeutic way.
Figure 2. 
Initiation of HPV DNA replication. (A) Schematic representation of the viral proteins E1 and E2 required for 
replication of the HPV genome. E1 and E2 are approximately 650 and 370 amino acids in length, respectively. 
Locations of the different functional domains in each protein are indicated. OBD, origin binding domain 
helicase/ATPase N-terminal; TAD, transactivation domain; H, hinge region; DBD, DNA-binding domain. (B) 
Schematic diagram of the initiation of HPV DNA replication. (I) Replication is initiated by the recruitment of 
E1 (purple) and by E2 (green), to the viral origin [10].
7E1 and E2 Viral Proteins as Therapeutic Targets for Development of Antiviral Agents
DOI: http://dx.doi.org/10.5772/intechopen.88697
An interaction protein–protein essential in the HPV DNA replication is the 
interaction between HPV E1 and E2 proteins. There are diverse reported works with 
advances in identification of leader compounds that may interrupt protein–protein 
E1-E2 interactions. Some of these compounds showed nanomolar affinities and 
high specificity.
Yoakim and coworker [51] discovered a group of small molecules known as 
indanones, and this molecules showed the capability to inhibit specifically E1-E2 
protein interaction, which also have been identified as the first inhibitors for small 
molecules capable to antagonize the assembly of E1-E2 complex and the viral ori 
HPV11. It was identified a compound that inhibited E1-E2 protein interaction 
by means of high-performance sieving from the collection of over Boehringer 
Ingelheim 100,000 compounds, using a scintillation proximity assay (SPA). Also, 
more active analogues were synthesized that were capable to inhibit the E1-E2 
complex assembly with the HPV11 viral ori with low nanomolar power in vitro 
and with activity in cell culture. Structurally, this group of inhibitors presents an 
indandione system spirofused onto a substituted tetrahydrofuran ring which were 
denominated as indandione inhibitors. It was determined that these inhibitors 
act by joining to E2 TAD domain, the same protein region that interacts with E1 
[51, 52]. Crystalline structures, HPV11 E2 TAD by itself or as a complex with an 
indandione inhibitor, both provide a detailed comprehension of the mechanism in 
which indandione inhibitors join E2 to interrupt the interaction E1-E2. A compari-
son between both structures revealed that the union between the inhibitors caused 
insignificant alterations on the protein backbone, but it did induce a significant 
movement of several lateral amino acid chains at the union site. These changes in 
the lateral chain conformation, particularly from Tyr-19, His-32, Leu-94 y, and 
Glu-100 residues, resulted in the formation of a deep hydrophobic bag that is joined 
firmly to the inhibitor indandione fraction. The structure also revealed that the 
inhibitor carboxylate fraction, known by its importance for power, forms hydrogen 
bonds with amides from the protein backbone. Studies regarding the structure-
activity relationship (SAR) revealed that the carboxylate fraction is important in 
potency of the inhibitor. Mechanistic studies, including the use of isothermal titling 
calorimetry, showed that the indandione inhibitors join reversibly to E2 TAD with 
1:1 stoichiometry. Even though indandione inhibitors displayed a powerful activity 
against E2 proteins of low-risk viruses HPV6 and HPV11, these did not show any 
activity against high-risk types HPV16, HPV18, and HPV31. Cellular culture studies 
showed that indandione inhibitors are capable of antagonizing E1-E2 interaction of 
HPV6 and HPV11 [49].
3.1 Other labs’ approach
White and coworker addressed these issues in a series of detailed studies to iden-
tify inhibitors of the cooperative assembly of HPV E1 and E2 on the ori, focusing 
on HPV 6 and 11. They identified two series of inhibitors that bound to overlapping 
sites at the E1 binding interface on the E2 TAD. Results obtained from modeling 
works suggest that inhibitors derived from repaglinide form weak interactions with 
protein E2 TAD but occupy a bigger portion from the inhibitor union bag than the 
indandione series.
Both series of compounds were optimized for binding by medicinal chemistry 
approaches, and in both series the best compounds in each series had low nanomo-
lar activity against the HPV 11 E1-E2 interaction.
The fact that the potent repaglinide derivatives, with values IC50 at nanomolar 
range against HPV6 and HPV11 E2, and EC50 values in cellular DNA replication 
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assays of approximately 1 mM, make this series a promising route for development 
of small molecular inhibitors for E1-E2 interaction [53].
Capabilities of indandione compounds to inhibit HPV genome in vivo replica-
tion, especially low-risk HPV types, demonstrate for the first time the therapeutic 
potential of protein E2 as target for the development of small molecule inhibitors 
at HPV protein interaction, particularly in the case for treatment of anogenital 
warts caused by HPV6 and HPV11. Furthermore, location and characterization of 
the union bag for E2 TAD inhibitors provide a new potential therapeutic option 
for treatment of HPV infections. These studies have set the basis for the use of 
approaches based in structures for rational design or for virtual selection of inhibi-
tor compounds capable of joining to all or part of the identified inhibitor union bag.
Kantang and coworker worked in the prediction of the interactions of the 
helicase domain of the E1 protein of HPV16 and the TAD domain of HPV16; for 
this purpose, E1 protein domain was modeled (residue 421–622) from HPV16 
with I-TASSER server. The model with the best C-score was selected to coupling to 
structure E2 from HPV16 and HPV18 using ClusPro. Superposition of E1 HPV16 
and the crystalline structure of E1 HPV18 showed an RMSD of 1.39 Å, indicating 
structural similitude. A complex structure for HPV16 E1-E2 is also predicted as 
similar to crystalline structure of HPV18 E1-E2, with an RMSD value of 1.11 Å. An 
analysis of HPV16 E1-E2 interactions revealed there are three sites for interaction 
of complex HPV16 E1 and E2. The residues Glu118, and Tyr178 at the structural 
domain of folded β-sheet for HPV16 E2 form hydrogen bonds with Tyr578, Arg575, 
Ser574, Asp573 of HPV16 E1, respectively.
HPV16 E2 helicoidal N-terminal domain is the main union site for HPV16 E1 
protein where Asp13, Thr17, Tyr19, Asp22, Tyr32, Glu39, and Val58 from HPV16 E2 
interact with Arg615 (for Asp13 and Thr17 E2), Arg447, Arg619, Glu452, Arg447, 
and Tyr602 from HPV16 E1, respectively. Shows Gln95 and Glu100; at the linking 
segment between N-terminal and C-terminal HPV16 E2, there are interactions 
with Arg462 and Ser455 from HPV16 E1, respectively. Besides, structures of nine 
peptides reported [54] were built by I-TASSER server. Using ClusPro web server, 
it was able to predict binding, conformations, and interactions of peptides with 
HPV16 E2 protein; bind conformations and interactions between small peptides 
and HPV16 E2 protein were predicted and analyzed. These results were used 
ahead for the design of more powerful peptides that may potentially inhibit E1-E2 
complex formation. Binding affinities obtained for designed peptides and protein 
E2 of HPV16 recombinant were in good agreement with experimental results. Four 
peptides were the more efficient inhibitors of E1-E2 complex, and they could be 
used for suppression of HPV replication [55].
4. Conclusions
Currently a cure or treatment for HPV is unavailable. In many men and women, 
HPV disappears by itself without causing further problems. There are treatments 
for affections caused by the virus. Among these affections are genital warts, pre-
carcinogenic cells, and cancer.
Even though there are vaccines against the main HPV types, there are therapeu-
tic treatments needed for those that have been already exposed to the virus which 
represent most of the population affected by this disease. In this regard, a diversity 
of research work related to antiviral design exists, including those work using com-
putational methods. These studies have laid the foundation for the use of structure-
based approaches to rationally design or virtually screen inhibitory compounds that 
are capable of preventing HPV replication.
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By means of molecular coupling analysis, it is possible to predict interactions 
of leader molecules with the target with enough detail to be useful for synthetic 
elaboration of those molecules.
It has been considered that protein-protein interactions are difficult to inhibit 
because they often involve big surfaces, depriving small molecules to bind with 
the pocket; however, they are receiving great attention to work as targets for the 
rational design of drugs. The interest in the protein-protein interaction inhibitors 
and in the protein drugs has been in constant growth.
Regarding HPV therapy development, a group of small molecules has been 
identified using high-performance sieving capable of interrupting HPV16 E1-E2 
interaction which helps avoid viral replication.
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